Coatings for preventing balloon damage to polymer coated stents

• US 8,778,014 B1
• Filed: 03/31/2004
• Issued: 07/15/2014
• Est. Priority Date: 03/31/2004
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: DesNoyer, Jessica Rene, Pacetti, Stephen D., Dugan, Stephen Robert, Maslanka, Bozena
• Primary Examiner(s): DOWE, KATHERINE MARIE
• Application Number:
  US10/816,072
• Time in Patent Office: 3,758 Days
• Field of Search: 623/1.46
• US Class Current: 623/1.46
• CPC Class Codes: A61F 2/844 folded prior to deployment
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2/958 Inflatable balloons for placing stents or stent-grafts
• CPC Class Codes: A61F 2002/91533 characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2002/91583 by a bridge, whereby at least one of its ends is connected along the length of a strut between two consecutive apices within a band
• CPC Class Codes: A61L 2300/426 Immunomodulating agents, i.e. cytokines, interleukins, interferons
• CPC Class Codes: A61L 2400/10 Materials for lubricating medical devices
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 29/14 Materials characterised by their function or physical properties , e.g. lubricating compositions
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

A medical assembly is disclosed comprises a stent and a catheter having a balloon, wherein the coefficient of friction and/or the adhesion at the stent/balloon interface are reduced.

Claims

1. A medical assembly comprising:

a stent having a polymer coating and a catheter having a balloon supporting the polymer coated stent, a surface of the balloon being modified so as to provide a lower kinetic coefficient of friction, adhesion, or both, at the polymer coating surface/balloon surface interface as compared to the kinetic coefficient of friction, adhesion, or both, at the polymer coating surface/balloon surface interface of an unmodified surface of the same balloon so as to prevent or minimize coating damage to the polymer coating during expansion, deflation, withdrawal of the balloon, or any combination thereof;

wherein the surface of the balloon is modified with a blocking agent deposited on at least a portion of the balloon surface such that for the balloon about 0.5 μ

g to about 2 μ

g of the blocking agent is deposited per 1 mm² of the balloon surface; and

wherein the blocking agent is poly(butyleneterephthalate-co-ethylene glycol).

2. The assembly of claim 1, wherein

the modification of the surface of the balloon is with a polymer layer containing, blended, conjugated, linked or bonded to the blocking agent;

or

the balloon comprises or is made from a polymer containing, blended, conjugated, linked or bonded to the blocking agent.

3. The medical assembly of claim 1, wherein the polymer coating of the stent comprises a drug.

4. The medical assembly of claim 3, wherein the drug is a member of at least one genus selected from the group consisting of antiproliferative substances, antineoplastic substances, anti-inflammatory substances, antiplatelet substances, anticoagulant substances, antifebrin substances, antithrombin substances, antimitotic substances, antibiotic substances, antiallergic substances, and antioxidant substances.

5. The medical assembly of claim 3, wherein the drug is clobetasol, estradiol, dexamethasone, paclitaxel, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, or any combination thereof.

6. A medical assembly comprising:

a stent having a polymer coating and a catheter having a balloon supporting the polymer coated stent, a surface of the balloon being modified so as to provide a lower kinetic coefficient of friction, adhesion, or both, at the polymer coating surface/balloon surface interface as compared to the kinetic coefficient of friction, adhesion, or both, at the polymer coating surface/balloon surface interface of an unmodified surface of the same balloon so as to prevent or minimize coating damage to the polymer coating during expansion, deflation, withdrawal of the balloon, or any combination thereof;

wherein the surface of the balloon is modified with a blocking agent deposited on at least a portion of the balloon surface such that about 0.5 μ

g to about 2 μ

g of the blocking agent is deposited per 1 mm² of the balloon surface; and

wherein the blocking agent is selected from the group consisting of glucose, sucrose, dextrose, maltose, mannose, trehalose, and combinations thereof.

7. The medical assembly of claim 6, wherein the blocking agent is glucose.

8. The medical assembly of claim 6, wherein the blocking agent is sucrose.

9. The medical assembly of claim 6, wherein the blocking agent is dextrose.

10. The medical assembly of claim 6, wherein the blocking agent is maltose.

11. The medical assembly of claim 6, wherein the blocking agent is mannose.

12. The medical assembly of claim 6, wherein the blocking agent is trehalose.

13. The medical assembly of claim 6, wherein the polymer coating of the stent comprises a drug.

14. The medical assembly of claim 13, wherein the drug is a member of at least one genus selected from the group consisting of antiproliferative substances, antineoplastic substances, anti-inflammatory substances, antiplatelet substances, anticoagulant substances, antifebrin substances, antithrombin substances, antimitotic substances, antibiotic substances, antiallergic substances, and antioxidant substances.

15. The medical assembly of claim 13, wherein the drug is clobetasol, estradiol, dexamethasone, paclitaxel, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, or any combination thereof.